- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01373333
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)
July 18, 2016 updated by: The Cleveland Clinic
Compassionate use of orphan drug 3,4-Diaminopyridine(DAP) in Treatment of Lambert Eaton Myasthenic Syndrome (LEMS).
3,4-DAP is used to decrease the muscle weakness associated with LEMS and hopefully will decrease the need for prednisone and all other therapies that were previously required to control symptoms.
How long a patient will take 3,4 DAP depends upon if he/she is seeing benefits from the medication or experiencing side effects that will prevent them from continuation in the study.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
3,4-diaminopyridine (3,4-DAP) decreases symptoms of weakness in patients with LEMS, and therefore can be used to decrease the amount of immune modulation therapy needed to provide an equivalent degree of disease control.
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44139
- Cleveland Clinic Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of LEMS with or without any of the following: evidence of underlying malignancy, presence of P/Q or N-type calcium channel antibodies, electrodiagnostic evidence of a presynaptic defect of neuromuscular junction transmission.None of these laboratory findings are required for inclusion in this study.
- P/Q and N type calcium channel antibodies are measured in the blood as a routine laboratory test during the course of initial diagnosis, but 10-20% of patients with LEMS do not have elevated levels of these antibodies.
Exclusion Criteria:
- Hypersensitivity to any component of this medication.
- History of past or current seizures.
- History of asthma.
- Evidence of prolonged QT syndrome. There is no absolute upper limit of normal for the QTc interval.
- Family history of prolonged QTc syndrome, history of unexplained syncope, seizures or cardiac arrest.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kerry H Levin, M.D., The Cleveland Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 1997
Primary Completion (Anticipated)
September 1, 2012
Study Registration Dates
First Submitted
June 13, 2011
First Submitted That Met QC Criteria
June 13, 2011
First Posted (Estimate)
June 14, 2011
Study Record Updates
Last Update Posted (Estimate)
July 20, 2016
Last Update Submitted That Met QC Criteria
July 18, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Disease
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Myasthenia Gravis
- Syndrome
- Lambert-Eaton Myasthenic Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Membrane Transport Modulators
- Neuromuscular Agents
- Potassium Channel Blockers
- Amifampridine
Other Study ID Numbers
- 102,384
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lambert-Eaton Myasthenic Syndrome
-
David P. Richman, MDJacobus PharmaceuticalNo longer available
-
Catalyst Pharmaceuticals, Inc.CompletedA Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)Lambert Eaton Myasthenic SyndromeUnited States, Spain, Serbia, Russian Federation, Hungary, France, Germany, Poland
-
University of Colorado, DenverApproved for marketingLambert Eaton Myasthenic SyndromeUnited States
-
Jacobus PharmaceuticalCompletedLambert-Eaton Myasthenic Syndrome | Eaton-Lambert Myasthenic SyndromeUnited States
-
Louis H. Weimer, MDNo longer availableLambert Eaton Myasthenic Syndrome (LEMS)United States
-
Oregon Health and Science UniversityJacobus PharmaceuticalNo longer availableLambert-Eaton Myasthenic Syndrome (LEMS) | Congenital Myasthenia (CM)United States
-
argenxRecruitingCongenital Myasthenic SyndromeUnited States, Canada, France
-
Catalyst Pharmaceuticals, Inc.CompletedMyasthenic Syndromes, CongenitalUnited States
-
Ricardo MaselliCatalyst Pharmaceuticals, Inc.No longer availableCongenital Myasthenic SyndromeUnited States
-
Mayo ClinicCompletedCongenital Myasthenic SyndromeUnited States
Clinical Trials on 3,4 DAP
-
Jacobus PharmaceuticalCompletedLambert-Eaton Myasthenic Syndrome | Eaton-Lambert Myasthenic SyndromeUnited States
-
Foundation for Liver ResearchCompletedChronic Hepatitis BNetherlands, China
-
Ricardo MaselliCatalyst Pharmaceuticals, Inc.No longer availableCongenital Myasthenic SyndromeUnited States
-
Lahey ClinicApproved for marketingLambert-Eaton Myasthenic Syndrome | Congenital Myasthenic SyndromeUnited States
-
Catalyst Pharmaceuticals, Inc.No longer availableLambert-Eaton Myasthenic Syndrome | Congenital Myasthenic Syndrome | Nystagmus, AcquiredUnited States
-
Catalyst Pharmaceuticals, Inc.CompletedA Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)Lambert Eaton Myasthenic SyndromeUnited States, Spain, Serbia, Russian Federation, Hungary, France, Germany, Poland
-
Dokuz Eylul UniversityScientific and Technological Research Council of Turkey (TUBITAK)Not yet recruitingAdjustment Reaction | Divorced
-
Ospedale Sandro Pertini, RomaCompleted
-
University Hospital, ToulouseLaboratoire parole et langage; Laboratoire Information Avignon université; IRIT...Recruiting
-
David P. Richman, MDJacobus PharmaceuticalNo longer available